Dimension Therapeutics Inc. (NASDAQ:DMTX)’s share price was down 3% on Thursday . The company traded as low as $5.70 and last traded at $5.90, with a volume of 59,908 shares traded. The stock had previously closed at $6.08.

A number of equities analysts recently weighed in on DMTX shares. Canaccord Genuity restated a “buy” rating on shares of Dimension Therapeutics in a report on Saturday, May 14th. Zacks Investment Research upgraded shares of Dimension Therapeutics from a “sell” rating to a “buy” rating and set a $7.50 target price on the stock in a report on Tuesday, May 17th. Jefferies Group started coverage on shares of Dimension Therapeutics in a report on Thursday, June 2nd. They set a “buy” rating and a $12.00 target price on the stock. Cantor Fitzgerald started coverage on shares of Dimension Therapeutics in a report on Thursday, June 2nd. They set a “buy” rating and a $32.00 target price on the stock. Finally, Chardan Capital set a $10.00 target price on shares of Dimension Therapeutics and gave the stock a “hold” rating in a report on Sunday. Three research analysts have rated the stock with a hold rating and six have issued a buy rating to the company’s stock. Dimension Therapeutics has an average rating of “Buy” and a consensus price target of $17.19.

The company’s market cap is $147.67 million. The company’s 50-day moving average is $6.77 and its 200-day moving average is $7.34.

Dimension Therapeutics (NASDAQ:DMTX) last issued its earnings results on Thursday, August 11th. The company reported ($0.49) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.43) by $0.06. Analysts predict that Dimension Therapeutics Inc. will post ($1.91) EPS for the current year.

In related news, SVP K. Reed Clark sold 5,000 shares of the stock in a transaction on Tuesday, June 7th. The stock was sold at an average price of $10.00, for a total value of $50,000.00. Following the transaction, the senior vice president now directly owns 5,000 shares in the company, valued at approximately $50,000. The sale was disclosed in a document filed with the SEC, which is available through the SEC website.

An institutional investor recently bought a new position in Dimension Therapeutics stock. Jennison Associates LLC bought a new position in Dimension Therapeutics Inc. (NASDAQ:DMTX) during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor bought 742,454 shares of the company’s stock, valued at approximately $8,265,000. Jennison Associates LLC owned approximately 2.97% of Dimension Therapeutics at the end of the most recent quarter.

Dimension Therapeutics, Inc is a gene therapy company. The Company is focused on discovering and developing therapeutic products for people living with rare diseases associated with the liver and caused by genetic mutations. It has programs for hemophilia B, hemophilia A, ornithine transcarbamylase (OTC) deficiency, and glycogen storage disease type Ia (GSDIa).

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.